Top Markets
Coin of the day
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
株式のランク #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
株価
$8.16
最終同期: 2025-06-26
時価総額
$234.57M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Regulus Therapeutics Inc. (RGLS)

カテゴリー

Regulus Therapeutics Inc.(RGLS)のP/B比率
September 2026 時点のP/B比率 TTM: 6.02
Regulus Therapeutics Inc. の最新の財務報告および株価によると、現在のP/B比率(TTM)は 6.02 です。2023 年末時点でのP/B比率は 1.15 でした。
Regulus Therapeutics Inc. の P/B 比率の履歴(2010 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
2026 (TTM) 6.02 414.32%
2024 1.17 1.71%
2023 1.15 82.40%
2022 0.63 25.85%
2021 0.50 -72.50%
2020 1.81 136.39%
2019 0.77 -155.41%
2018 -1.39 -145.10%
2017 3.07 44.92%
2016 2.12 -41.35%
2015 3.61 -32.55%
2014 5.36 76.06%
2013 3.04 265.18%
2012 0.83 -3,304.62%
2011 -0.03 -119.29%
2010 0.13 0.00%
同業他社のP/B比率
企業 P/B比率 P/B比率の差
6.828 13.47%
US
7.5116 24.83%
NL
8.2199 36.60%
US
3.9942 -33.62%
AU
- -
CH